fluconazole has been researched along with Asymptomatic Conditions in 5 studies
Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.
fluconazole : A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "For persons with symptomatic cryptococcal meningitis, optimal initial management with amphotericin and flucytosine improves survival compared to alternative therapies; however, amphotsericin is difficult to administer and flucytosine has not been available in middle or low income countries, where cryptococcal meningitis is most prevalent." | 2.55 | Recent advances in AIDS-related cryptococcal meningitis treatment with an emphasis on resource limited settings. ( Abassi, M; Boulware, DR; Lofgren, S; Rhein, J, 2017) |
| "Cryptococcosis is a systemic infection and it may occur in immunocompromised and immunocompetent hosts." | 1.56 | Clinical analysis in immunocompetent and immunocompromised patients with pulmonary cryptococcosis in western China. ( Liu, X; Lu, Y; Lv, X; Qu, J; Zhang, X, 2020) |
| "Most had confirmed cryptococcal meningitis, and 54% (14/26) of the symptomatic CrAg+ persons were dead or lost at 6 months." | 1.48 | A Prospective Evaluation of a Multisite Cryptococcal Screening and Treatment Program in HIV Clinics in Uganda. ( Boulware, DR; Huppler Hullsiek, K; Lofgren, S; Meya, DB; Nalintya, E; Rajasingham, R, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Qu, J | 1 |
| Zhang, X | 1 |
| Lu, Y | 1 |
| Liu, X | 1 |
| Lv, X | 1 |
| Nalintya, E | 1 |
| Meya, DB | 1 |
| Lofgren, S | 2 |
| Huppler Hullsiek, K | 1 |
| Boulware, DR | 2 |
| Rajasingham, R | 1 |
| Kapoor, SW | 1 |
| Magambo, KA | 1 |
| Kalluvya, SE | 1 |
| Fitzgerald, DW | 1 |
| Peck, RN | 1 |
| Downs, JA | 1 |
| Abassi, M | 1 |
| Rhein, J | 1 |
| Matsumoto, M | 1 |
| Kita, Y | 1 |
| Gocho, T | 1 |
| Wakiyama, S | 1 |
| Sakamoto, T | 1 |
| Iida, T | 1 |
| Misawa, T | 1 |
| Ishida, Y | 1 |
| Yanaga, K | 1 |
1 review available for fluconazole and Asymptomatic Conditions
| Article | Year |
|---|---|
Recent advances in AIDS-related cryptococcal meningitis treatment with an emphasis on resource limited settings.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Amphotericin B; Anti-HIV | 2017 |
4 other studies available for fluconazole and Asymptomatic Conditions
| Article | Year |
|---|---|
Clinical analysis in immunocompetent and immunocompromised patients with pulmonary cryptococcosis in western China.
Topics: Adult; Asymptomatic Diseases; Central Nervous System; China; Cryptococcosis; Cryptococcus; Diagnosti | 2020 |
A Prospective Evaluation of a Multisite Cryptococcal Screening and Treatment Program in HIV Clinics in Uganda.
Topics: Adult; Antifungal Agents; Antigens, Fungal; Asymptomatic Diseases; CD4 Lymphocyte Count; Cryptococco | 2018 |
Six-month outcomes of HIV-infected patients given short-course fluconazole therapy for asymptomatic cryptococcal antigenemia.
Topics: Adult; Antifungal Agents; Asymptomatic Diseases; Cryptococcosis; Female; Fluconazole; HIV Infections | 2015 |
Successful liver transplantation from a living donor with asymptomatic pulmonary cryptococcosis.
Topics: Antifungal Agents; Asymptomatic Diseases; Cryptococcosis; Cryptococcus neoformans; Drug Administrati | 2011 |